1. Home
  2. IMAB

IMAB

I-MAB

Logo I-MAB

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
.
-
-
%

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.

Founded: 2014 Country:
China
China
Employees: N/A City: N/A
Market Cap: 146.1M IPO Year: 2020
Target Price: $12.25 AVG Volume (30 days): 407.5K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.29 EPS Growth: N/A
52 Week Low/High: $1.16 - $3.76 Next Earning Date: 04-19-2024
Revenue: $3,899,013 Revenue Growth: -68.60%
Revenue Growth (this year): -90.41% Revenue Growth (next year): 38.46%

Share on Social Networks: